B · Normal
[Tuoxin Pharmaceutical: Subsidiary safinamide mesylate API has been approved for marketing] On September 22, Tuoxin Pharmaceutical (301089.SZ) announced that the company's wholly-owned subsidiary Xinxiang Pharmaceutical's safinamide mesylate API has received the "Chemical API Marketing Application Approval Notice" issued by the State Food and Drug Administration. This drug is a MAO-B selective inhibitor and is used for patients with moderate to advanced Parkinson's disease. After approval, the company's product line will be expanded and the market competitiveness of APIs will be enhanced. However, sales performance is affected by multiple factors and there is a risk of not being as good as expected.
A-share announcement express 🕐 2026-09-22 16:22
#Chemical #A-share announcement express
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Tianchuang Fashion: Plans to change securities abbreviation to "Tianchuang Shar 09-22 17:34 [Honghe Technology: Shareholders reduced their holdings by 2.5% in total] On Sep 09-22 17:27 [Happy Home: The controlling shareholder plans to transfer 3.80% of the shares t 09-22 17:24 [Mingxin Xuteng: Shareholders holding more than 5% of the shares plan to transfe 09-22 17:21 [Yinglite: Temporary suspension of production of some production devices] On Sep 09-22 17:08 [Sanda Film: Persons acting in concert with the actual controller plan to increa 09-22 16:48

Comments

0/500
Captcha (click to refresh)
No comments yet